|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the expression of ERCC1 in squamous carcinoma was significantly higher compared with in adenocarcinoma samples.
|
28927101 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
|
29200955 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A matched chemotherapy regimen meant that platinum plus docetaxel was administered in patients negative for ERCC1 and negative for tubulin, platinum plus pemetrexed in patients with adenocarcinoma positive for tubulin, negative for ERCC1 and negative for TYMS, and platinum plus TS-1 in those with SCC positive for tubulin, negative for ERCC1 and negative for TYMS.
|
28476819 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Higher Ki67, APC, ERCC1 expressions and lower TTF1 expression were identified in advanced stages (IIA and IIIA) of adenocarcinomas, which reflect a more aggressive, less differentiated, possibly a non-TRU adenocarcinoma.
|
25926247 |
2016 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of TS gene was evidently higher in patients with adenocarcinoma than those with non-adenocarcinoma (P=0.013) and so was the expression of ERCC1 (P=0.003).
|
25921119 |
2015 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ERCC1 mRNA levels were higher in tumors from patients with metastatic disease than patients with non-metastatic disease (P = 0.021), and higher in adenocarcinomas than squamous cell carcinomas (P = 0.006).
|
24762590 |
2014 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
When AC and SCCA were assessed separately, the statistical significance between gene expression and sex was lost (in SCCA: ERCC1, p = 0.14; RRM1, p = 0.26; TS, p = 0.11).
|
23470290 |
2013 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ERCC1 gene +262A/C polymorphism associated with risk of gastric cardiac adenocarcinoma in nonsmokers.
|
22374244 |
2012 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Using 8F1, low ERCC1 was correlated with the adenocarcinoma histotype, increased tumor size and clinical stage, high pT and pN category and the presence of metastasis.
|
21030862 |
2011 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
ERCC1 shows a significant prognostic value in ABTA patients treated with cisplatin.
|
21298384 |
2011 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Median ERCC1 expression overall was 1.82 (range, 0.22-27.31) and was histology related: AC, median = 1.68 (0.22-11.33) and squamous, median = 2.42 (0.51-14.28) (p < 0.001).
|
20975603 |
2010 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk.
|
18478337 |
2008 |